Evidence map›Paper›PMID 42160635›Full record

ArticleThe Journal of urology2026

Urine Tumor DNA Testing Identifies Recurrence and Monitors Therapy Response in Patients With High-Risk Nonmuscle-Invasive Bladder Cancer Receiving Intravesical Bacillus Calmette-Guérin.

Henning Bahlburg, Moritz Maas, Alberto Contreras-Sanz, Dalia Othman, Marie-Pier St-Laurent, Jussi Nikkola, Shoujie Chai, Kevin G Phillips, Barbara Hamlington, Peter S Lentz and 6 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Henning BahlburgDepartment of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Moritz MaasDepartment of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Alberto Contreras-SanzDepartment of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Dalia OthmanDepartment of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Marie-Pier St-LaurentDepartment of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Jussi NikkolaDepartment of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Shoujie ChaiConvergent Genomics Inc, South San Francisco, California.ORCID 0000-0002-5621-8725
Kevin G PhillipsConvergent Genomics Inc, South San Francisco, California.ORCID 0000-0003-1062-3802
Barbara HamlingtonConvergent Genomics Inc, South San Francisco, California.
Peter S LentzConvergent Genomics Inc, South San Francisco, California.
Nicolai P LumbresConvergent Genomics Inc, South San Francisco, California.
Vincent T BicoccaConvergent Genomics Inc, South San Francisco, California.ORCID 0000-0002-5702-4586
Tuomas JalankoDepartment of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Trevor G LevinConvergent Genomics Inc, South San Francisco, California.ORCID 0000-0003-1323-1126
Dirk LangeDepartment of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Peter C BlackDepartment of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIntravesical bacillus Calmette-Guérin (BCG) is the preferred treatment for high-risk nonmuscle-invasive bladder cancer. However, many patients recur within the first year despite optimal therapy. Urine tumor DNA (utDNA) offers promise in stratifying therapy response to identify patients who may benefit from treatment intensification or de-escalation. Our study aimed to validate utDNA testing in a multicenter cohort of patients receiving BCG. MATERIALS AND

methodsPretreatment/posttreatment urine from patients undergoing BCG for nonmuscle-invasive bladder cancer was analyzed by utDNA testing (UroAmp). utDNA disease classification (positive/negative) and genomic disease burden were determined according to previously established tumor-naïve algorithms. Kaplan-Meier recurrence-free survival (RFS) analyses were conducted to compare groups and Cox proportional hazards assessed.

resultsForty percent (23/57) of patients were utDNA positive before the first BCG treatment. utDNA-positive patients had a 12-month RFS of 61% compared with 85% for negative patients (HR = 3.2,

conclusionsutDNA analysis reliably stratifies risk of recurrence in patients receiving BCG and shows promise to identify early recurrence enabling personalized treatment.

Indexed as

Adjuvants, ImmunologicBCG VaccineDNA, NeoplasmNeoplasm Recurrence, LocalUrinary Bladder NeoplasmsAdministration, IntravesicalAgedFemaleHumansMaleMiddle AgedNon-Muscle Invasive Bladder NeoplasmsRisk AssessmentTreatment OutcomeAdjuvants, ImmunologicBCG VaccineDNA, Neoplasmbacillus Calmette-Guérinbladder cancerminimal residual diseaseurine biomarkerurine tumor DNA

Identifiers

PMID42160635
PMCPMC13456551

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.